- Home
- SOC vs HAE Comparison
SOC vs HAE Comparison
Compare SOC & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOC
- HAE
- Stock Information
- Founded
- SOC 2020
- HAE 1971
- Country
- SOC United States
- HAE United States
- Employees
- SOC N/A
- HAE N/A
- Industry
- SOC
- HAE Medical/Dental Instruments
- Sector
- SOC
- HAE Health Care
- Exchange
- SOC Nasdaq
- HAE Nasdaq
- Market Cap
- SOC 3.0B
- HAE 3.3B
- IPO Year
- SOC N/A
- HAE 1991
- Fundamental
- Price
- SOC $22.17
- HAE $71.13
- Analyst Decision
- SOC Buy
- HAE Strong Buy
- Analyst Count
- SOC 4
- HAE 9
- Target Price
- SOC $30.50
- HAE $99.78
- AVG Volume (30 Days)
- SOC 3.0M
- HAE 505.1K
- Earning Date
- SOC 08-12-2025
- HAE 08-07-2025
- Dividend Yield
- SOC N/A
- HAE N/A
- EPS Growth
- SOC N/A
- HAE 44.54
- EPS
- SOC N/A
- HAE 3.31
- Revenue
- SOC N/A
- HAE $1,360,824,000.00
- Revenue This Year
- SOC N/A
- HAE N/A
- Revenue Next Year
- SOC N/A
- HAE $7.18
- P/E Ratio
- SOC N/A
- HAE $21.49
- Revenue Growth
- SOC N/A
- HAE 3.96
- 52 Week Low
- SOC $13.66
- HAE $55.30
- 52 Week High
- SOC $35.00
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- SOC 38.85
- HAE 60.48
- Support Level
- SOC $22.31
- HAE $68.62
- Resistance Level
- SOC $23.73
- HAE $73.78
- Average True Range (ATR)
- SOC 1.56
- HAE 1.53
- MACD
- SOC -0.51
- HAE -0.20
- Stochastic Oscillator
- SOC 2.11
- HAE 60.51
About SOC Sable Offshore Corp. Common Stock
Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California. The company is managed as one reportable segment, oil and gas.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.